Literature DB >> 26092487

Reply to Planche et al.

Krishna Rao1, Vincent B Young2, David M Aronoff3.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26092487      PMCID： PMC4560910          DOI： 10.1093/cid/civ480

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  13 in total

1.  Assessment of Clostridium difficile infections by quantitative detection of tcdB toxin by use of a real-time cell analysis system.

Authors:  Alex B Ryder; Ying Huang; Haijing Li; Min Zheng; Xiaobo Wang; Charles W Stratton; Xiao Xu; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2010-08-18       Impact factor: 5.948

2.  Fecal-Free Toxin Detection Remains the Best Way to Detect Clostridium difficile Infection.

Authors:  Tim Planche; Mark Wilcox; A Sarah Walker
Journal:  Clin Infect Dis       Date:  2015-06-19       Impact factor: 9.079

3.  Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality.

Authors:  Krishna Rao; Dejan Micic; Mukil Natarajan; Spencer Winters; Mark J Kiel; Seth T Walk; Kavitha Santhosh; Jill A Mogle; Andrzej T Galecki; William LeBar; Peter D R Higgins; Vincent B Young; David M Aronoff
Journal:  Clin Infect Dis       Date:  2015-03-31       Impact factor: 9.079

Review 4.  Diagnosis and treatment of Clostridium difficile in adults: a systematic review.

Authors:  Natasha Bagdasarian; Krishna Rao; Preeti N Malani
Journal:  JAMA       Date:  2015-01-27       Impact factor: 56.272

Review 5.  Clostridium difficile colitis.

Authors:  C P Kelly; C Pothoulakis; J T LaMont
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

6.  Clinical relevance of a positive molecular test in the diagnosis of Clostridium difficile infection.

Authors:  I Baker; J P Leeming; R Reynolds; I Ibrahim; E Darley
Journal:  J Hosp Infect       Date:  2013-07-05       Impact factor: 3.926

7.  Impact of the type of diagnostic assay on Clostridium difficile infection and complication rates in a mandatory reporting program.

Authors:  Yves Longtin; Sylvie Trottier; Gilles Brochu; Bianka Paquet-Bolduc; Christophe Garenc; Vilayvong Loungnarath; Catherine Beaulieu; Danielle Goulet; Jean Longtin
Journal:  Clin Infect Dis       Date:  2012-09-25       Impact factor: 9.079

8.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Authors:  Stuart H Cohen; Dale N Gerding; Stuart Johnson; Ciaran P Kelly; Vivian G Loo; L Clifford McDonald; Jacques Pepin; Mark H Wilcox
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

9.  Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity.

Authors:  Romney M Humphries; Daniel Z Uslan; Zachary Rubin
Journal:  J Clin Microbiol       Date:  2012-12-26       Impact factor: 5.948

10.  Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection.

Authors:  Timothy D Planche; Kerrie A Davies; Pietro G Coen; John M Finney; Irene M Monahan; Kirsti A Morris; Lily O'Connor; Sarah J Oakley; Cassie F Pope; Mike W Wren; Nandini P Shetty; Derrick W Crook; Mark H Wilcox
Journal:  Lancet Infect Dis       Date:  2013-09-03       Impact factor: 25.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.